Excellent Overall Survival in Head & Neck Cancer Patients
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- Immutep Quarterly Activities Report Q3 FY25
- Immutep to Participate in Upcoming Investor Conferences
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
- First patient dosed in phase 3 TACTI-004 lung cancer trial
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Later from Immutep
- Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
- High Response Rates achieved in Lung Cancer in INSIGHT-003
- Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
- Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial
- Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep